January 6, 2019 - The 2nd Annual Neuroscience Innovation Forum
for BD&L and Investment in Therapeutics and Technology
The program will cover BioPartnering for CNS, with industry keynotes and panels on AD, PD, Neuropsychiatry and Pain Management. Moreover there are panels on innovation in NeuroTech covering banking, device, diagnostics and software.
Venue: Marines' Memorial Club, San Francisco, CA, USA
Meet with our Team! Send Us a Request to Meet
January 7-9, 2019 - Biotech Showcase: San Francisco's Exclusive Investor and Networking Event
DISCOVER. INVEST. CURE.
The investor conference that drives the future of drug development
Venue: HILTON SAN FRANCISCO UNION SQUARE, San Francisco, CA 94102 USAMeet with our Team! Send Us a Request to Meet
January 7-10, 2019 - 37TH Annual J.P. Morgan Healthcare Conference
Venue: San Francisco, CaliforniaMeet with our Team! Send Us a Request to Meet
Feb. 11 - 12, 2019 - BIO CEO & Investor Forum
The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies. Because our mission is to support industry-wide success, we present a broad and unbiased view of investment opportunities.
Venue: New York, New York, USAMeet with our Team! Send Us a Request to Meet
Feb 26 - 28, 2019 - Biocom's Global Life Science Partnering Conference
Biocom's 9th Annual Global Life Science Partnering Conference is an exclusive global partnering and networking forum that brings together senior executives, bankers, venture capitalists, and business development professionals from leading pharmaceutical and biotech companies. Join us in San Diego, February 26th to February 28th, 2019, where industry leaders will debate current trends, companies will showcase their latest technologies and all attendees will have the opportunity to schedule one-on-one meetings with leading deal-makers.
Venue: The Lodge at Torrey Pines, La Jolla, CA, USA
Meet with our Team! Send Us a Request to Meet
March 9-14, 2019 - Annual Meeting of the Society of Toxicology
Dr. Jack Snyder, who currently serves as a member of the Board of Directors of the American Board of Toxicology, will attend the Annual Meeting of the Society of Toxicology scheduled for March 9-March 14, 2019 in Baltimore, MD.
Jack also will be on-site for educational symposia sponsored by the American College of Toxicology that are scheduled for April 8-12, May 13-17, and August 5-9 in Gaithersburg, MD. Dr. Snyder is board-certified in general toxicology, medical toxicology, addiction medicine, and toxicological chemistry, and currently serves as Asst. Managing Director in CATO's Washington office.
Venue: Baltimore, MD, USAMeet with our Team! Send Us a Request to Meet
March 20, 2019 - NCBIO's Legislative Reception
More than 150 life science company representatives and legislators will join us for an evening reception highlighting North Carolina's life sciences industry. Please note that additional information will be sent regarding registration.
Venue: Raleigh, NC, USAMeet with our Team! Send Us a Request to Meet
March 25-27, 2019 - BIO Europe Spring
This year's event in Vienna will bring together the "who's who" from the biotech, pharma and finance segments to allow delegates to meet more key decision makers in three days of partnering meetings than they could in a whole year.
Venue: Messe Wien Exhibition and Congress Center, Vienna, AustriaMeet with our Team! Send Us a Request to Meet
April 12-15, 2019 - Annual Meeting of the Academy of Clinical Research Professionals
Dr. Jack Snyder, Asst. Managing Director in CATO's Washington office, will attend the Annual Meeting of the Academy of Clinical Research Professionals scheduled for April 12-April 15, 2019 in Nashville, TN. Jack not only serves as a member of ACRP's Certified Physician Investigator (CPI) Job Analysis Task Force, but also serves as a member of the committee that oversees ACRP's certification examination for principal investigators.
Venue: Nashville, TN, USAMeet with our Team! Send Us a Request to Meet
May 14 - 16, 2019 - Israeli MIXiii BIOMED Conference
The Full Spectrum of Healthcare: From Prevention to Rehabilitation and Everything in Between
This year's conference is co-organized by leading Israeli and international healthcare institutions with the objective of exposing participants to thought leaders and experts and allow local and global attendees to mix and exchange knowledge and ideas.
As the leading event of Israel's life sciences industry, MIXiii-BIOMED has positioned itself as the main annual meeting place for both Israeli and international players. It presents a unique and exuberating occasion to participate in discussions, panel presentations, product demonstrations and networking opportunities, all paving the way for new business collaborations.
Venue: David InterContinental Hotel, Tel Aviv, IsraelMeet with our Team! Send Us a Request to Meet
May 31 - Jun 4, 2019 - 2019 ASCO Annual Meeting
Caring for Every Patient, Learning from Every Patient | #ASCO19
Venue: McCormick Place, Chicago, IL, USAMeet with our Team! Send Us a Request to Meet
June 3-6, 2018 - BIO International Convention 2019
The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.
BIO performs many services for members, but none of them are more visible than the BIO International Convention. The BIO International Convention helps BIO fulfill its mission to help grow the global biotech industry. Profits from the BIO International Convention are returned to the biotechnology industry by supporting BIO programs and initiatives. BIO works throughout the year to create a policy environment that enables the industry to continue to fulfill its vision of bettering the world through biotechnology innovation.
Venue: Philadelphia, PA, USAMeet with our Team! Send Us a Request to Meet
Jun 23 - 27, 2019 - Join Cato Research during DIA for a Wine Tasting at the historical William Heath Davis House Museum
Date TBD - More information to come!
Venue: William Heath Davis House Museum, San Diego, CA, USAMeet with our Team! Send Us a Request to Meet
Jun 23 - 27, 2019 - DIA 2019 Global Annual Meeting
The DIA 2019 Global Annual Meeting brings together thousands of innovators from around the globe. Designed to drive insights into action by connecting key policy discussions to real-world knowledge that you need to do your job every day, your attendance will accelerate your growth and your organization's performance in the development ecosystem.
Venue: San Diego Convention CenterMeet with our Team! Send Us a Request to Meet
Sep. 11, 2019 - RESI (Redefining Early Stage Investments) Boston
Fundraising CEOs have a venue to meet early stage investors that are a fit for their sector and stage every three months, providing a great ROI for cost conscious CEOs.
Venue: Boston, MA, USAMeet with our Team! Send Us a Request to Meet
Sep. 11-12, 2019 - BioPharm America 2019: 12th Annual International Partnering Conference BioPharm America
BioPharm America is where biotech industry partnerships get started. Meet face-to-face with biotech and pharma executives from around the world to identify and enter strategic relationships. Equipped with partneringONE, the world's leading web-based partnering system for the life science industry, BioPharm America is the only event in North America based on the same reputable formula as EBD Group's acclaimed European events BIO-Europe and BIO-Europe Spring.
Venue: Hynes Convention Center, Boston, MA, USAMeet with our Team! Send Us a Request to Meet
Oct 2-4, 2019 - Cell & Gene Meeting on the Mesa
Venue: Carlsbad, CA, USAMeet with our Team! Send Us a Request to Meet
Oct 22-23, 2019 - BioInvestor Forum
The BIO Investor Forum is an international biotech investor conference focused on early and established private companies as well as emerging public companies. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and BIO One-on-One Partnering™ meetings.
Venue: San Francisco, California, USAMeet with our Team! Send Us a Request to Meet
October 21-22, 2019 - NORD Summit 2019
Rare Diseases and Orphan Products Breakthrough SummitNetworking With Today's Rare Disease Innovators
Cutting-Edge Keynote Speakers
6 Breakout Sessions
Expansive poster session
over 800 leaders from FDA, NIH, industry, patient groups, payers and research institutions addressed the New Era of Patient-Focused Innovation attended last year. Together, NORD Rare Summit attendees explored the new and innovative ways in which patients and caregivers are helping drive progress for the rare disease community.
Why You Should Attend:
Venue: Washington, D.C., USAMeet with our Team! Send Us a Request to Meet
Nov 11-13, 2019 - BIO EU Fall
Initiate new partnerships through life science partnering
Venue: Hamburg, GermanyMeet with our Team! Send Us a Request to Meet
Dec. 7-10, 2019 - 61st ASH Annual Meeting and Exposition
The premier event in malignant and non-malignant hematology
Venue: Orange County Convention Center (OCCC), Orlando, FL, USAMeet with our Team! Send Us a Request to Meet
November 28, 2018
Cato Research Partners with Water Street and JLL Partners to Continue Growth and Expansion
April 21, 2018
Cato Research Cancer Advances Proudly Sponsors PurpleStride Raleigh-Durham 2018
March 23, 2018
Cato Research awarded "Best International Clinical Trial Services Provider 2018"
Lynda Sutton, principle and cofounder of Cato BioVentures, a family owned venture capital of Cato Holdings, was recently featured in BioWorld's article titled, "Alternative to traditional venture capital money could fill translational gaps" by Jennifer Boggs, for her panel discussion at this year's January RESI conference featuring Cato BioVentures' innovative investment approaches in the healthcare sector:
"Cato Bioventures, for instance, started investing in gene therapy in 2000. "We're finally seeing early results," said Lynda Sutton, principal and co-founder.
Launched in 1988 as the venture capital affiliate of Cato Holding, a privately held family fund, has built a portfolio of firms, including those developing therapeutics, medical devices and stem cell therapies. It invests in firms at all stages of development and across multiple therapeutic areas, and its funds have gone into both public and private firms. Cato Bioventures offers a two-pronged approach to its investments, said Sutton, who, like de Souza, is another pharma veteran. The first is to look for technology "that needs a home, bring it in and form a company around it," with the aim of getting it to a value inflection point. The second involves looking for companies with good management, promising technology and invest money and resources to complement drug development efforts."
October 2, 2017
Mallinckrodt plc (NYSE:MNK) today announced it has entered into a licensing agreement for development and commercialization of NeuroproteXeon's investigational, pharmaceutical-grade xenon gas for inhalation therapy being evaluated to improve survival and functional outcomes for patients resuscitated after a cardiac arrest.
April 29, 2017
Cato Research and Cancer Advances Proudly Sponsors PurpleStride Raleigh-Durham 2017
May 10, 2016
Cancer Advances Proudly Sponsors PurpleStride Raleigh-Durham 2016
May 05, 2016
Manufacturing has begun for Cancer Advances' Lead Product
March 28, 2016
NeuroproteXeon Appoints Cato Research for Phase III Trials
NeuroproteXeon Appoints Cato Research for Phase III Trials
On January 29th Mervyn Maze, MB, ChB, Chief Medical Officer of NeuroproteXeon announced CATO Research of Durham, North Carolina as the Clinical Research Organization (CRO) administering the Company's Phase III trial. Dr. Maze indicated the selection reflects CATO's three decades of experience in international trial administration, their broad international scope, and the ease with which NP and CATO management interacted.
Present plans are for a nine country, approximately 30 sites, 1,300 patent trial, comparing hypothermia with hypothermia plus Xenon. The primary outcome will be survival from cardiac arrest. It is anticipated the trial will be complete in less than two years following FDA/ EMA approval of the Company's IND application.
CATO commences work with NP immediately. By the end of February, NP's draft protocol will be expanded and forwarded to the Trial Executive Committee. They will edit the protocol in March and submit it to the FDA for a Special Protocol Assessment later that month. This usually occurs within 45 days of submission. Following agreement with the Agency on trial design, the protocol will be incorporated in our Investigational New Drug Application.
The timing of the protocol assessment dovetails well with drug profiling and device development. The Praxair Drug Master File for cGMP Xenon, which we will reference, will be filed in March.
The tranche of additional toxicology tests requested by FDA will be completed and reported by June. Prototypes of both the clinical test device and consumable breathing circuit/ absorber will be available for validation and verification in mid-March. The devices will be ready for submission in early July.
The plan is anticipated to come together to allow device manufacture, site qualification and training in the fourth quarter and initial patient enrollment in January, 2017.
March 8, 2016
Cancer Advances attends PanCAN
© 2018 Cato Research. All rights reserved.